Companies: 10,795·Total market cap: $144.5T
Anika Therapeutics, Inc.

Anika Therapeutics, Inc.

ANIKNASDAQHealthcare● Active
$14.60
+$0.12(+0.83%)
Market Cap$194262110
P/E Ratio
52W High$16.24
52W Low$7.87
Overview

Anika Therapeutics, Inc. (ANIK) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000898437 · ANIK · NASDAQ · as of Jun 10, 2026

Filing snapshot

1,000+
Total Filings
DEFA14A
Latest Form
2026-06-08
Most Recent
1993
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0000898437 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-03
Fiscal Year End
Mar 3, 2026
Accession No.
0001171843-26-001275
Primary Document
anik20251231_10k.htm
Source: data.sec.gov · CIK 0000898437 · Accession 0001171843-26-001275

Latest Key Filings

10-QQuarterly Report
FORM 10-Q
2026-04-30
8-KCurrent Report
FORM 8-K
2026-04-29Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
DEFA14AProxy Statement (Additional)
DEFA14A
2026-06-08
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-06-01
View
10-QQuarterly Report
FORM 10-Q
2026-04-30
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-29
View
8-KCurrent Report
FORM 8-K
2026-04-29
View
ARSARS
ARS
2026-04-28
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-28
View
DEF 14AProxy Statement
DEF 14A
2026-04-28
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
10-KAnnual Report
FORM 10-K
2026-03-03
View
8-KCurrent Report
8-K
2026-02-26
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-01-27
View
8-KCurrent Report
8-K
2026-01-08
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-01-08
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2025-11-21
View
Showing 1–15 of 569 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000898437  |  Exchange: NASDAQ · Healthcare

Anika Therapeutics, Inc. (NASDAQ: ANIK) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1993. As a Healthcare sector company with CIK 0000898437, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Anika Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Anika Therapeutics, Inc. 10-K was filed on 2026-03-03 for fiscal year ending 2026. Historical ANIK 10-K annual reports are available from 2003 through 2026.

Investors researching Anika Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10

Frequently Asked Questions

ANIK SEC Filings · 8 questions

Anika Therapeutics, Inc. (ANIK) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. Anika Therapeutics, Inc.'s CIK is 0000898437.

ANIK SEC filingsAnika Therapeutics, Inc. SEC documentsfind ANIK 10-K